IO360° offers an unparalleled opportunity to hear from stakeholders representing both the science and business communities who report on the latest data impacting IO to fight a wider range of cancers.

Click here to register!

Attend our presentation

From the Science to Investing: What Biotechs Need to Know on Sourcing Innovation, Investing and Partnering in IO in Today’s Current Market

Time: 10:20am EST
Day: February 9, 2023


  • Jeffrey Bockman, PhD, EVP, BioConsulting, Head of Oncology, Lumanity


  • Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics
  • Sharon Benzeno, PhD, CCO, Immune Medicine, Adaptive Biotechnologies
  • Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist Securities


This panel will address what new and emerging biotech’s need to know and prepare for in order to rise above the noise in the IO biotech space when sourcing investments and partnerships. Biopharma business leaders address key questions biotechs have including:

  • What is our preclinical and early clinical development strategy that will get the biggest bang for the buck where the runways and cash available may be constrained?
  • How do we stand out in the noise of IO where there are thousands of biotechs saturating this space?
  • What does it take to get a Series A and/or a partnership in this current investing environment?